CONNECT1903: A Pilot and Surgical Study of Larotrectinib for Treatment of Children with Newly-Diagnosed High-Grade Glioma with NTRK Fusion.
International Sponsor: CONNECT (Collaborative Network for NEuro-oncology Clinical Trials), U.S.A
Status: Open
For more information: Click Here
COZMOS: Phase I/Ib trial of Combined 5’aZacitidine and carboplatin for recurrent/refractory paediatric brain and solid tuMOurS
International Sponsor: The Hospital for Sick Kids (Toronto, Canada)
Status: Closed to recruitment
For more information: Click Here
INFORM2: Exploratory multinational phase I/II combination study of Nivolumab and Entionstat in children and adolescents with refractory high-risk malignancies.
International Sponsor: KiTZ – Hopp Children’s Cancer Centre, (Heidelberg, Germany)
Status: Open
For more information: Click Here
MET-MED: Phase III randomized double-blind placebo-controlled trial of metformin for white matter repair and cognitive recovery in pediatric brain tumor patients
International Sponsor: The Hospital for Sick Kids (Toronto, Canada)
Status: Under development
For more information: Click Here
OZM-075: Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers
International Sponsor: The Hospital for Sick Kids (Toronto, Canada)
Status: Closed to recruitment
For more information: Click Here
PNOC-019/ NICHE-HGG: A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High-Grade Glioma (HGG).
International Sponsor: PNOC (Pacific Pediatric Neuro-Oncology Consortium), U.S.A
Status: Open
For more information: Click Here
PNOC-022/ DMG-ACT: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
International Sponsor: PNOC (Pacific Pediatric Neuro-Oncology Consortium), U.S.A
Status: Open
For more information: Click Here
ReRAD: A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma.
SJ- ELIOT: Phase 1 Evaluation of LY2606368, A Molecularly-Targeted CHK1/2 Inhibitor Therapy, In Combination with Cyclophosphamide or Gemcitabine for Children and Adolescents with Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumours.
International Sponsor: St Jude Children’s Research Hospital (Memphis, U.S.A)
Status: Closed to recruitment
For more information: Click Here